Michael Lincoff, MD: Lipid Levels & Cardiovascular Outcomes With CETP Inhibition
AUGUST 29, 2016
At the European Society of Cardiology Congress 2016 (ESC) in Rome, Italy, Michael Lincoff, MD, Cleveland Clinic explained results from ACCELERATE trial involving patients with high risk vascular disease who received evacetrapib on top of standard care. They assessed the increase and decrease of HDL and LDL cholesterol. Lincoff did point out that despite the beneficial effects on lipids, this did not result in a reduction in sudden cardiovascular events, which was a surprising finding -- there were no differences in any of the endpoints or in the subgroups defined by baseline cholesterol or whether they were on statin therapy.